Gino K. In, MD, MPH, and Lara A. Dunn, MD, review updated long-term follow-up data on cosibelimab from the CK-301-101 study and discuss what its efficacy, durability, and tolerability mean for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
Gino K. In, MD, MPH, of the USC Norris Comprehensive Cancer Center, and Lara A. Dunn, MD, of Memorial Sloan Kettering Cancer Center, open a discussion of newly reported long-term follow-up data on cosibelimab in locally advanced cutaneous squamous cell carcinoma.
Dr. Dunn describes how she uses immune checkpoint inhibitors in locally advanced cutaneous squamous cell carcinoma, distinguishing neoadjuvant therapy from checkpoint blockade given as a replacement for curative therapy.
Dr In walks through the updated locally advanced disease cohort data from the CK-301-101 study of cosibelimab, presented at the 2026 ASCO Annual Meeting.
Dr Dunn interprets the efficacy and durability findings from the updated cosibelimab locally advanced cohort, characterizing the overall response rate exceeding 50% and the unreached median duration of response at 31 months of follow-up as impressive.
Dr In reviews the safety and tolerability profile of cosibelimab in the updated locally advanced cohort, an older patient population in which tolerability carries particular weight.
Dr In and Dr Dunn turn to remaining unmet needs in advanced cutaneous squamous cell carcinoma, focusing on high-risk populations routinely excluded from pivotal trials, including solid organ transplant recipients, patients with hematologic malignancies, and those with autoimmune disease.
Dr Dunn delivers key takeaways for community oncologists and dermatologists managing advanced cutaneous squamous cell carcinoma.
